Background: Feline immunodeficiency virus (FIV) remains one of the most important chronic viral infections affecting domestic cats, yet the therapeutic landscape for FIV has developed more slowly than that for many human viral diseases. The references provided for the present article span antiviral pharmacology, herpesvirus treatment experience in feline and human ophthalmic disease, structural studies of FIV proteolytic processing, feline lentiviral protease inhibition, antiviral assembly targeting, and host restriction mechanisms. When examined together, these studies offer a useful basis for understanding how antiviral development for FIV can be approached in a mechanistically coherent way.

Objective: This article aimed to generate a publication-ready integrative research synthesis assessing the efficacy and therapeutic promise of antiviral strategies relevant to FIV, with particular emphasis on protease inhibition, viral assembly disruption, and host-directed restriction approaches, while also drawing conceptual lessons from established antiviral treatment paradigms in herpesvirus infections.

Methodology: A qualitative integrative review design was used. The included references were analyzed through a structured thematic framework covering antiviral principles, translational lessons from feline herpesvirus and herpes simplex therapy, FIV molecular processing targets, protease inhibitor design, retroviral assembly inhibition, and innate or synthetic host restriction strategies. Evidence was interpreted comparatively, with attention to mechanism of action, translational value, potential resistance concerns, and clinical applicability.

Results: The reviewed literature indicates that the most compelling FIV-directed antiviral evidence centers on protease biology and protease inhibition. Identification of gag and pol processing sites established the molecular basis for rational drug targeting (Elder et al., 1993). Subsequent substrate specificity analyses enabled development of broad-based inhibitors active against FIV, simian immunodeficiency virus, and human immunodeficiency virus in vitro and ex vivo (Lee et al., 1998). Therapeutic benefit in an in vivo disease context was supported by TL-3–mediated prevention and resolution of neurological deficits in FIV infection (Huitron-Resendiz et al., 2004). Response patterns to tipranavir further suggested the value of FIV as a comparative model for drug-resistant retroviral protease inhibition (Norelli et al., 2008). Additional conceptual promise was identified in capsid assembly targeting, antiviral interference with virion morphogenesis, and synthetic feline TRIM5-CypA restriction systems (Neira, 2009; Prevelige, 2011; Dietrich et al., 2010; Dietrich et al., 2011; Towers, 2007). Lessons from herpesvirus therapy underscore the importance of mechanism-specific intervention, timely treatment, and resistance-aware drug development (De Clercq, 2004; James and Prichard, 2014; Stiles, 1995; Thomasy et al., 2016; Luntz and MacCallum, 1963; Kaufman, 1980).

Conclusion: Current evidence supports a strategically layered model for FIV treatment in which protease inhibition remains the strongest direct antiviral approach, while assembly inhibitors and host-directed restriction strategies represent important next-generation directions. Progress in FIV therapeutics will depend on integrating molecular precision, feline-specific pharmacologic evaluation, and resistance-conscious combination design.